CATAFLAM
LOE ApproachingNDAORALTABLET
Approved
Nov 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CATAFLAM is an oral tablet small-molecule nonsteroidal anti-inflammatory drug (NSAID) approved in 1993 by Novartis. The product treats pain and inflammation across multiple indications through inhibition of cyclooxygenase enzymes. It is a mature branded NSAID in an era of significant generic and OTC competition.
LOE Approaching
Moderate competitive pressure (30%) suggests stable but contracting market position; brand team likely focused on differentiation and cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CATAFLAM roles center on defending market share and managing decline in a generic-dominated NSAID category. Career progression on this asset is limited; professionals should view assignments as consolidation experience or stepping stones to growth-stage products.
Brand ManagerField Sales Representative
Worked on CATAFLAM at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.